Rhythm Management

Innovative technologies designed to improve and extend the lives of patients with arrhythmias and heart failure

Innovative portfolio with differentiated technologies

HeartLogic™ Heart Failure Diagnostic

Demonstrated 67% reduction in heart failure hospitalizations

LUX-DX™ ICM

53% reduction in false positives

EMBLEM™ MRI S-ICD

Only FDA-approved subcutaneous ICD device

With the broadest diagnostics portfolio and differentiated ICD/CRT-D and S-ICD technologies, we can help you strengthen quality outcomes, increase operational efficiencies, enhance patient experience and improve the financial health of your cardiovascular service line.


HeartLogic Heart Failure Diagnostic

Predict potential heart failure events weeks in advance

HeartLogic demonstrated 67% reduction in heart failure readmissions with Resonate ICDs and CRT-Ds featuring HeartLogic. Multiple sensors are used to track physiologic trends and send a proactive alert of potential worsening heart failure.

Multiple Sensors

Heart Sounds
Reveals signs of elevated filling pressure and weakend ventricular contraction

Thoracic Impedance
Measures fluid accumulation and pulmonary edema

Respiration
Monitors rapid shallow breathing pattern associated with shortness of breath

Heart Rate
Indicates cardic status and arrhythmias

Activity
Shows activity levels and reflects the patient's overall status and fatigue

The impact of heart failure on quality of life and healthcare economics

1.1 Million+
hospitalizations attributed to heart failure each year6

25%
of heart failure patients are readmitted within 30 days of initial hospitalization7,8

$100 Billion
approximate expected heart failure spend by 20309

Improve efficiencies and patient outcomes

The MulitSENSE study assessed more than 900 patients and validated that the HeartLogic algorithm provides a sensitive and timely predictor of impending heart failure decompensation.16

70% sensitivity
in detecting heart failure events

A median of 34 days
advance notice of worsening heart failure

<2 total alerts
per patient per year

Watch to discover how HeartLogic™ can reduce heart failure-related hospitalizations.


LUX-Dx™ Insertable Cardiac Monitor (ICM) System

It’s time for actionable, high-quality data

The LUX-Dx ICM provides long-term arrhythmia monitoring, including advanced detection of AF, palpitations, cryptogenic stroke, ventricular tachycardia and syncope.

  • Reduces false positives by 53% with dual-stage algorithm3
  • Connects patients with the myLUX Patient App to improve efficiencies and enhance patient satisfaction
  • Reduces ICM patient workload with remote programming
  • Achieves more efficient and confident S-ECG evaluations with help from clear signals

The need for better detection is clear

5.3 M

People in the U.S. have atrial fibrillation1

13%

Of AF cases go undiagnosed1

450k+

Hospitalizations each year with AF as the primary diagnosis2


BodyGuardian® Family

Ambulatory ECG drives new patients to Cath Lab procedures

The BodyGuardian® family product portfolio includes short, medium, and long-term Holter, cardiac event and mobile cardiac telemetry monitors. BodyGuardian provides advanced detection of AF, palpitations, ventricular tachycardia and syncope.

500k+

Patients remotely monitored with diagnostics each year in the U.S4

100k

Studies with an AF diagnosis5

  • Identify clinically significant arrhythmias with BeatLogic® deep-learning and artificial intelligence
  • Identify arrhythmias earlier, to improve clinical outcomes
  • Obtain near real-time analysis of AECG data with PatientCare cloud-based platform
  • Increase efficiency with Split-Bill and Patient Care models 

EMBLEM™ MRI S-ICD

The only FDA-approved Subcutaneous ICD Device

EMBLEM MRI S-ICD is the only subcutaneous implantable defibrillator that provides protection from both sudden cardiac death and the risks associated with transvenous leads.

Minimize risks associated with transvenous leads

200k+

De Novo transvenous ICDs are implanted worldwide each year11

14x

Higher rate of lead complications requiring surgical intervention with transvenous ICDs than S-ICD12

54.8%

Of first time ICD recipients were candidates for S-ICD13

  • High conversion success of 98.4%14, similar to that reported with TV-ICD trials
  • Protection from risks associated with transvenous leads, S-ICD demonstrated fewer lead and device-related complications than TV-ICD over a 4-year follow up15
  • Reduces the need for fluoroscopy during the implant procedure, helping to improve efficiencies

Solutions for optimizing heart failure patient management

Boston Scientific is offering a growing selection of offerings specifically tailored to propel your cardiovascular business forward and address complex challenges.

Contact Us

Get in touch with a sales representative to discuss how our portfolio of product and solutions can deliver measurable outcomes in the cardiovascular service line.


References:

1. Turakhia MP, et al. (2018) Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS  ONE 13(4): e0195088
2. Benjamin EJ, et al. Heart disease and stroke statistics - 2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528
3. Bench testing showed a relative reduction of 53.1% in false positives when QRS morphology was turned on
4. Data Sources: Medicare 2016-2019
5. Data Source: Based on patients monitored between March 2020 – April 2021.
6. After Hospitalization: A Dartmouth Atlas Report on Post-Acute Care for Medicare Beneficiaries, Sept 28th, 2011
7. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. J AMA. 2007;297(1):61–70. 
8. ’Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008
9. https://circ.ahajournals.org/content/123/8/933?ijkey=ef69d682d9a0210be678bba2f4bd7f3bac3b1239&keytype2=f_ipsecsha
10. Boehmer, J et al., JACC-HF, 2017;5(3),216-25
11. Mond HG, Proclemer A. The 11th World Survey of Cardiac Pacing and Implantable Cardioverted-Defibrillators: A Calendar Year 2009 - A World Society of Arrhythmia's Project, Pacing. Clin Electrophysiol. 34 (2011) 1013–1027. 
12. Brouwer, et al. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy. JACC 2016;68(19):2047-2055  
13. Friedman DJ, et al. Trends and In-Hospital Outcomes Associated with Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States. JAMA Cardiology 2016
14. Gold, MR, et al. The UNTOUCHED Study. Circulation. 2020
15. Knops RE, Olde NordkampLRA, DelnoyPHM, et al. Subcutaneous or Transvenous Defibrillator Therapy (PRAETORIAN). N EnglJ Med. 2020;383(6):526-536
16. Boehmer JP, Hariharan R, Devecchi FG, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study. JACC Heart Fail. 2017 Mar;5(3):2
17. doi: 10.1016/j.jch